Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1950 1
1951 2
1952 1
1953 1
1954 1
1955 5
1956 1
1957 1
1958 1
1959 1
1960 1
1961 5
1962 2
1964 2
1966 1
1971 1
1983 1
1984 1
1993 1
1995 1
1996 1
1998 2
2000 2
2003 2
2005 2
2007 1
2008 2
2009 3
2010 2
2011 1
2012 1
2013 2
2014 1
2015 2
2016 6
2017 8
2018 4
2019 3
2020 6
2021 11
2022 11
2023 2

Text availability

Article attribute

Article type

Publication date

Search Results

100 results

Results by year

Filters applied: . Clear all
Page 1
PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer.
Roncolato F, Lindemann K, Willson ML, Martyn J, Mileshkin L. Roncolato F, et al. Among authors: lindemann k. Cochrane Database Syst Rev. 2019 Oct 7;10(10):CD012160. doi: 10.1002/14651858.CD012160.pub2. Cochrane Database Syst Rev. 2019. PMID: 31588998 Free PMC article. Review.
Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis.
Poveda A, Lheureux S, Colombo N, Cibula D, Lindemann K, Weberpals J, Bjurberg M, Oaknin A, Sikorska M, González-Martín A, Madry R, Pérez MJR, Ledermann J, Davidson R, Blakeley C, Bennett J, Barnicle A, Škof E. Poveda A, et al. Among authors: lindemann k. Gynecol Oncol. 2022 Mar;164(3):498-504. doi: 10.1016/j.ygyno.2021.12.025. Epub 2022 Jan 19. Gynecol Oncol. 2022. PMID: 35063276 Free article. Clinical Trial.
Association of patient-reported outcomes and ovarian cancer recurrence.
Kargo AS, Jensen PT, Lindemann K, Hjøllund NH, Liposits GI, Raaschou-Jensen N, Knudsen BM, Möller S, Hansen DG, Steffensen KD. Kargo AS, et al. Among authors: lindemann k. Int J Gynecol Cancer. 2021 Sep;31(9):1248-1259. doi: 10.1136/ijgc-2021-002550. Epub 2021 Jun 18. Int J Gynecol Cancer. 2021. PMID: 34489355
Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial.
Landen CN, Molinero L, Hamidi H, Sehouli J, Miller A, Moore KN, Taskiran C, Bookman M, Lindemann K, Anderson C, Berger R, Myers T, Beiner M, Reid T, Van Nieuwenhuysen E, Green A, Okamoto A, Aghajanian C, Thaker PH, Blank SV, Khor VK, Chang CW, Lin YG, Pignata S. Landen CN, et al. Among authors: lindemann k. Clin Cancer Res. 2023 May 1;29(9):1698-1707. doi: 10.1158/1078-0432.CCR-22-2032. Clin Cancer Res. 2023. PMID: 36595569 Free PMC article.
The ethics of receiving.
Lindemann K. Lindemann K. Theor Med Bioeth. 2003;24(6):501-9. doi: 10.1023/b:meta.0000006927.95755.a8. Theor Med Bioeth. 2003. PMID: 14750546 Review.
100 results